GlassScriptPhysician profile
Jesse V Mcclain
NPI 1396891792
$78,970.55
in general payments reported to CMS, 2019-2025
26 companies · $3,894 in 2025
The $3,894 reported for 2025 was more than what 97% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32K · 2022: $25K · 2023: $7,234 · 2024: $11K · 2025: $3,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $2,192 · Travel and Lodging: $1,388 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,562.50 |
| Food and Beverage | $2,192.29 |
| Travel and Lodging | $1,387.65 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73,141.22 | 2021-2025 | |
| Allergan, INC. | $1,850.00 | 2021 | |
| Livanova USA, INC. | $1,462.10 | 2021-2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $680.16 | 2021-2023 | Tysabri |
| E.R. Squibb & Sons, L.L.C. | $339.49 | 2023-2025 | Zeposia |
| Amgen INC. | $262.50 | 2021-2022 | |
| Sk Life Science, INC. | $260.98 | 2021-2022 | |
| Genzyme Corporation | $162.52 | 2021-2022 | |
| Abbott Laboratories | $136.17 | 2024 | Amplatzer Talisman |
| Ucb, INC. | $100.29 | 2021-2022 | |
| Argenx US, INC. | $70.22 | 2025 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $55.95 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.52 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $43.26 | 2021-2022 | |
| Cala Health, INC. | $43.17 | 2024 | Cala Kiq, Cala Trio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.78 | 2021-2022 | |
| Genentech USA, INC. | $40.40 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $36.57 | 2021 | |
| Alexion Pharmaceuticals, INC. | $34.12 | 2022 | |
| Janssen Biotech, INC. | $29.79 | 2025 | Tremfya |
| Pfizer INC. | $28.08 | 2023 | |
| Emd Serono, INC. | $25.91 | 2021 | |
| Kyowa Kirin, INC. | $22.27 | 2021 | |
| Impel Pharmaceuticals INC. | $19.48 | 2022 | |
| Lilly USA, LLC | $18.21 | 2022 | |
| Ge Healthcare | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.